

POLICY ON ACCESS TO MEDICINES

ROVI GROUP

Revision approvals		
Revision No.	Date of entry into force	Approved by
0	26/05/2022	Juan López Belmonte- CEO



Introduction

In general terms, the mission of Laboratorios Farmacéuticos ROVI is to work in favour of the well-being of society and enhance the quality of life of patients and the attention provided to them, promoting human health through the research, manufacture, marketing and distribution of medicines and other healthcare products. For this reason, Laboratorios Farmacéuticos Rovi believes that the pharmaceutical industry plays an important role in developing medicines and treatments that meet society's healthcare needs.

Although ROVI is aware of that important role that the pharmaceutical industry should play when providing society with healthcare solutions, it also acknowledges that the principal onus of establishing efficient healthcare systems for all citizens falls upon governments.

The lack of access to medicines and to a high-quality healthcare system is one of the main barriers that prevents societies from reaching greater levels of well-being and social and economic development.

Therefore, ROVI considers that an efficient healthcare system is the main tool to combat health inequalities and the problems of access to health and that, although governments hold the main responsibility for establishing efficient healthcare systems, the pharmaceutical industry can and should also help to reduce the gap between those who have access to a high-quality healthcare system and those who do not. Therefore, ROVI will try to contribute to make it possible.

How we act

ROVI's goal is to enhance people's quality of life. Therefore, it places its knowledge and experience at the disposal of society to favour the attainment of this goal, helping its stakeholders and communities to make healthcare and medicines accessible. To this end, ROVI does the following:

- **Ensures the continuity of the production and supply of medicines:** ROVI carries on an essential activity and, therefore, it must ensure the continuity of its operations to guarantee that its medicines are available at all times to the patients who need them. ROVI has created incident management teams (IMCR) who immediately analyse the specific risks and needs of each one of its production centres to ensure the continuity of the production of essential medicines, as well as the supply chain to ensure they are distributed correctly.
- **Ensures the distribution of its medicines:** ROVI is a European company whose operational and industrial activity is based in Spain. Likewise, it has subsidiaries in the United Kingdom, France, Germany, Italy and Portugal, from which it markets its products. Additionally, ROVI signs marketing agreements with different partners so that its medicines are available and accessible in practically the entire world.

In 2021, ROVI distributed its medicines in 89 countries. It has signed license agreements with international partners for their distribution in over 100 countries and is working to increase its international presence in the long term.



- **Has a “one-off distribution” system to send our medicines to wherever they are necessary:** when ROVI receives a request for supply to a country where its medicines are required, the Group has a one-off distribution procedure in which, without the need for a contract and guaranteeing compliance with all regulatory obligations, it sends our medicines to the territories where they are needed.
- **Cooperates in emergencies and/or exceptional situations:** during healthcare emergencies and/or exceptional situations, ROVI works with international and local entities to ensure a swift response to the express demand for its medicines. In these cases, the collaboration may be commercial, in order to meet a specific need for its medicines in countries where ROVI is not present, or it may be humanitarian, urgently supplying its medicines either through non-governmental organisations deployed in the area affected by the emergency or by making a donation in kind.

Regarding one of the ROVI’s areas of specialisation, it is important to highlight the fact that the World Health Organisation has recommended low-molecular-weight heparins as essential medicines to treat COVID-19. The development of programmes for the donation in kind of our low-molecular-weight heparins may play an essential role in saving lives and improving the quality of life of people in catastrophic situations.

Likewise, ROVI considers that long-term donations of medicines and/or donations to treat chronic diseases are not a sustainable solution to overcome the healthcare challenges that exist in many countries. For this reason, product donations to treat chronic diseases, such as schizophrenia, or recurring product donations would only be made under exceptional circumstances with the prior approval of ROVI’s Donations Committee, which is the body responsible for evaluating and deciding on specific requests for donations from the Group.

- **ROVI Group donations policy:** ROVI has a donations policy that regulates the possibility of making donations, either in cash or in kind, with which ROVI supports social care programmes. These donations are usually made to local or international non-profit organisations or institutions oriented towards the research or development of public aid programmes.
